Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cue Biopharma, Inc. (CUE : NSDQ)

• Company Description    Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts. Number of Employees: 59

• Price / Volume Information    Yesterday's Closing Price: $3.30 Daily Weekly Monthly 20 Day Moving Average: 389,674 shares Shares Outstanding: 35.37 (millions) Market Capitalization: $116.73 (millions) Beta: 1.62 52 Week High: $18.42 52 Week Low: $3.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.34% -18.25% 12 Week -44.91% -38.08% Year To Date -70.82% -64.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 40 GUEST STREET - BOSTON,MA 02135 USA ph: 617-949-2680 fax: - ir@cuebio.com http://www.cuebiopharma.com

• General Corporate Information    Officers Daniel R. Passeri - Chief Executive Officer and Director Kerri-Ann Millar - Chief Financial Officer Aaron Fletcher - Director Cameron Gray - Director Peter A. Kiener - Director Peer Information Cue Biopharma, Inc. (CORR.) Cue Biopharma, Inc. (RSPI) Cue Biopharma, Inc. (CGXP) Cue Biopharma, Inc. (BGEN) Cue Biopharma, Inc. (GTBP) Cue Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 22978P106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 35.37 Most Recent Split Date: (:1) Beta: 1.62 Market Capitalization: $116.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.41 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.55 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.68 Price/Cash Flow: - Price / Sales: 8.11 EPS Growth vs. Year Ago Period: -7.32% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -35.61% vs. Previous Quarter: -87.88% ROE 03/31/22 - -68.89 12/31/21 - -65.04 09/30/21 - -65.79 ROA 03/31/22 - -53.60 12/31/21 - -51.85 09/30/21 - -52.56 Current Ratio 03/31/22 - 6.66 12/31/21 - 5.35 09/30/21 - 4.58 Quick Ratio 03/31/22 - 6.66 12/31/21 - 5.35 09/30/21 - 4.58 Operating Margin 03/31/22 - -319.09 12/31/21 - -295.57 09/30/21 - -654.55 Net Margin 03/31/22 - -319.09 12/31/21 - -295.57 09/30/21 - -654.55 Pre-Tax Margin 03/31/22 - -315.65 12/31/21 - -292.26 09/30/21 - -651.69 Book Value 03/31/22 - 1.96 12/31/21 - 2.06 09/30/21 - 2.02 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.15 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 13.23 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©